Results 201 to 210 of about 51,036 (300)

Redundant pharmacovigilance disproportionality analyses: Navigating between Scylla and Charybdis. [PDF]

Headache
Khouri C, Hlavaty A, Salvo F, Donati M, Raschi E.   +4 more
europepmc   +1 more source

Neuropsychiatric Outcomes Associated With GLP‐1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity Status

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptors are expressed in brain regions governing mood, reward and stress, yet the neuropsychiatric effects of GLP‐1 receptor agonist (GLP‐1 RA) therapy remain poorly characterized. We estimated associations between GLP‐1 RA use and neuropsychiatric disorders and variation by obesity status and treatment ...
Seo Hyon Baik, Fitsum Baye, Haotian Xian, Kin Wah Fung, Clement J. McDonald   +4 more
wiley   +1 more source

Bringing Gene Therapy Into Real World Clinical Practice

Haemophilia, EarlyView.
ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach, Pratima Chowdary, Margareth C. Ozelo   +2 more
wiley   +1 more source

Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national database. [PDF]

Jpn J Clin Oncol
Frey C.
europepmc   +1 more source

Pregnancy outcomes following exposure to galcanezumab: Analysis of cases from the galcanezumab clinical trials and postmarketing database

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study was conducted to describe pregnancy outcomes reported following maternal or paternal exposure to galcanezumab in clinical trials and postmarketing surveillance. Background Galcanezumab is a calcitonin gene‐related peptide‐inhibiting monoclonal antibody indicated for the preventive treatment of migraine.
Irene Boz, Jan Lewis Brandes, Christopher Robinson, Maria Fernanda Scantamburlo Fernandes, Sarah Lipsius, LaRonda Morford, Enemona Emmanuel Adaji, Anaclara Prada Jardim, Holland C. Detke   +8 more
wiley   +1 more source

From Product-Quality Complaints to Patient-Safety Triage: A Structured Narrative Review and Proposed PRCS-TRACE Framework. [PDF]

Healthcare (Basel)
Cenaj S, Llanaj E.
europepmc   +1 more source

Longitudinal effects of CGRP‐targeting migraine therapies on blood pressure and body mass index: A 12‐month retrospective analysis

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To compare blood pressure (BP) and body mass index (BMI) trajectories associated with individual calcitonin gene‐related peptide (CGRP)‐targeting migraine therapies versus matched CGRP‐unexposed controls. Background CGRP is a potent vasodilator with established roles in vascular homeostasis and metabolic regulation.
Phillip Phan, Scott Keith, Michael Li, Richard Hass, Wan‐Jen Hsieh, Michael Marmura, Hsiangkuo Yuan   +6 more
wiley   +1 more source

Pharmacovigilance signals for congenital heart disease related to drug exposure: A disproportionality analysis based on the FAERS database. [PDF]

Am Heart J Plus
He CL, Zhang XN, Zhao GX, Ma LJ, Feng R, Liu YH.   +5 more
europepmc   +1 more source

Cyclin‐dependent kinase 4/6 (CDK4/6) inhibitor‐induced hepatotoxicity and its resolution: a study of seven cases

Histopathology, EarlyView.
CDK4/6 inhibitor‐induced liver injury represents a clinically significant and histologically distinctive form of drug‐induced hepatotoxicity, most commonly encountered with ribociclib. The predominant pattern is severe acute hepatocellular injury, frequently accompanied by lymphocytic cholangitis, a combination that, in the appropriate clinical context,
Sunayana Misra, Lisa Centeno, Dupinder Singh, Romil Saxena, Rifat Mannan   +4 more
wiley   +1 more source

Comparator-Dependent Safety Signals for Incident Systemic Autoimmune Rheumatic Diseases After mRNA COVID-19 Vaccination: A Systematic Review. [PDF]

Vaccines (Basel)
Pinte L, Balanescu P, Dima A, Mandescu AM, Simion-Stanciu ME, Dumitru AC, Baicus C.   +6 more
europepmc   +1 more source